Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 7/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 7/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.54 |
| ▸ | CCNK | O75909 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 6/20 | 0.54 |
| ▸ | CCND1 | P24385 | 5/20 | 0.54 |
| ▸ | CCND2 | P30279 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067711 | 0.88 | CCND3 (0.58) | STAT6SYKCCND3CDK6CCNK | |
| SCHEMBL2386837 | 0.81 | STAT6 (1.00) | STAT6SYK | |
| SCHEMBL4067757 | 0.81 | CDK4 (0.64) | SYKCCND3CDK6CCNKCDK9 | |
| SCHEMBL4065441 | 0.81 | CDK4 (0.61) | CCND3CDK6CCNKCDK9CCNA2 | |
| SCHEMBL4071177 | 0.75 | IGF1R (0.62) | STAT6CCND3CDK6CCNKCDK9 | |
| SCHEMBL4066350 | 0.73 | CDK4 (0.56) | CCND3CDK6CCNKCDK9CCNA2 | |
| SCHEMBL4073235 | 0.72 | CDK4 (0.64) | CCND3CDK6CCNKCDK9CCNA2 | |
| SCHEMBL4076077 | 0.72 | SYK (0.61) | SYKCCND3CDK6CCNKCDK9 | |
| SCHEMBL736067 | 0.72 | SYK (1.00) | STAT6SYK | |
| SCHEMBL4069339 | 0.72 | SYK (0.59) | SYKCCND3CDK6CCNKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | claimed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | claimed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090030005-A1 | Combinations for the treatment of cancer | AMGEN INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1740184-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | STAT6 1684/4885SYK 2974/4885CCND3 32/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | STAT6 123/4885SYK 354/4885CCND3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.